{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:31:37Z","timestamp":1765233097671,"version":"build-2065373602"},"reference-count":31,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Chimeric antigen receptor T (CAR T) cell immunotherapy has shown remarkable efficacy in non-Hodgkin\u2019s lymphoma (NHL) patients. Minimal residual disease (MRD) monitoring in NHL is essential after CAR T cell therapy, which can be achieved by monitoring circulating tumor DNA (ctDNA). The mutation of TP53 in NHL has been suggested to be associated with a poor prognosis. However, whether TP53-mutated ctDNA can be used as a biomarker remains undetermined. In this study, a total of 40 patients with mutated TP53 who received CAR T cell treatment were analyzed, and specific probes targeting 29 different TP53 mutation sites in the 40 patients were designed and verified. Then, the presence of TP53-mutated ctDNA in longitudinal plasma samples was tracked by droplet digital PCR. Patients were stratified into two groups, favorable or unfavorable, based on their highest ctDNA level using a MAF cutoff of 3.15% according to the ROC curve. The unfavorable group had significantly worse PFS than the favorable group (p &lt; 0.001). Our results suggest that patients with mutated TP53 with a favorable ctDNA profile in the first trimester have better prognostic outcomes than patients with an unfavorable profile, and ctDNA can be a reliable predictor of the subsequent clinical outcome.<\/jats:p>","DOI":"10.3390\/diagnostics11050844","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T21:32:46Z","timestamp":1620595966000},"page":"844","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy"],"prefix":"10.3390","volume":"11","author":[{"given":"Liting","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolu","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40265-017-0690-8","article-title":"Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies","volume":"77","author":"Hay","year":"2017","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma","volume":"132","author":"Chow","year":"2018","journal-title":"Blood"},{"key":"ref_4","first-page":"426","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"1","author":"Schwarzenbach","year":"2011","journal-title":"Nat. Rev. Cancer Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1039\/c1lc20126c","article-title":"Multiplex digital PCR: Breaking the one target per color barrier of quantitative PCR","volume":"11","author":"Zhong","year":"2011","journal-title":"Lab Chip"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/1078-0432.CCR-13-2933","article-title":"Detection of cancer DNA in plasma of patients with early-stage breast cancer","volume":"20","author":"Beaver","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"a000919","DOI":"10.1101\/cshperspect.a000919","article-title":"The tumor suppressor p53: From structures to drug discovery","volume":"2","author":"Joerger","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_8","first-page":"a001016","article-title":"Clinical outcomes and correlates of TP53 mutations and cancer","volume":"2","author":"Robles","year":"2010","journal-title":"Csh Perspect. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Lundin","year":"2011","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","article-title":"Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: An international collaborative study","volume":"112","author":"Young","year":"2008","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Wu","year":"2012","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1134\/S0026893316060224","article-title":"Frequency, spectrum, and functional significance of TP53 mutations in patients with diffuse large B-cell lymphoma","volume":"51","author":"Voropaeva","year":"2017","journal-title":"Mol. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/bioinformatics\/btv195","article-title":"PROVEAN web server: A tool to predict the functional effect of amino acid substitutions and indels","volume":"31","author":"Choi","year":"2015","journal-title":"Bioinformatics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers?","volume":"25","author":"Baugh","year":"2017","journal-title":"Cell Death Differ."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nsmb.2114","article-title":"Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53","volume":"18","author":"Hagn","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: The promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and Safety of CAR19\/22 T-cell \u201cCocktail\u201d Therapy in Patients with Refractory\/ Relapsed B-Cell Malignancies","volume":"135","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2014.58.5729","article-title":"Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission","volume":"33","author":"Huntington","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.beha.2018.07.004","article-title":"Monitoring Clinical Outcomes in Aggressive B-cell Lymphoma: From Imaging Studies to Circulating Tumor DNA","volume":"31","author":"Christopher","year":"2018","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1078-0432.CCR-20-2558","article-title":"Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study","volume":"27","author":"Nadeu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2016-03-635219","article-title":"Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma","volume":"127","author":"Roschewski","year":"2016","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"ref_26","first-page":"14737159","article-title":"Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: A cancer diagnostic perspective","volume":"18","author":"Postel","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/sonc.2002.34878","article-title":"Hematologic malignancies: New developments and future treatments","volume":"29","author":"Cheson","year":"2002","journal-title":"Semin Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-230X(08)60785-X","article-title":"p 53 and Human Cancer: The First Ten Thousand Mutations","volume":"77","author":"Hainaut","year":"1999","journal-title":"Adv. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.cdd.4401910","article-title":"The P53 pathway: What questions remain to be explored?","volume":"13","author":"Levine","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3389\/fonc.2020.01460","article-title":"Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy","volume":"10","author":"Chasov","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_31","first-page":"842","article-title":"The TP53 tumor suppressor and autophagy in malignant lymphoma","volume":"8","author":"Young","year":"2015","journal-title":"Autophagy"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/5\/844\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:58:14Z","timestamp":1760162294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/5\/844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["diagnostics11050844"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics11050844","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2021,5,8]]}}}